Efficacy Clause Samples
POPULAR SAMPLE Copied 2 times
Efficacy. Except as specifically provided herein, this Amendment does not in any way waive, amend, modify, affect or impair the terms and conditions of the Purchase Agreement, and all terms and conditions of the Purchase Agreement are hereby ratified and confirmed and shall remain in full force and effect unless otherwise specifically amended, waived, modified or changed pursuant to the terms and conditions of this Amendment. This Amendment shall become effective upon its execution, which may occur in one or more counterparts in accordance with Section 5 hereof.
Efficacy. When tested against Pseudomonas aeruginosa and Staphylococcus aureus in 2 hours achieves at least a 4.0 log reduction at time zero and a log reduction of 3.0 throughout the shelf life. Reference WI-8.
Efficacy a. Descriptive statistics for all primary and secondary endpoints
Efficacy. DURATION - CESSATION This contract is valid from to In case the event shall last longer, the present can be extended prior to written agreement among the parties. The event organizer shall communicate to the Agency the reasons for requesting the extension of the present contract. The Agency once assessed these reasons, can grant a time extension or can decide to resolve the present contract without any claim by the organizer. The Agency retains the right to terminate the contract for breach at any time, with the exception of the already completed activities, giving a notice of 30 (thirty) working days. This notice shall be communicated through registered letter.
Efficacy. The Products that result from the practice of the USGN Know-How or the USGN Patent Rights will effectively neutralize or decontaminate the biological and/or chemical substances as set forth in Exhibit C and are fit for the purpose of neutralizing or decontaminating such substances as set forth in Exhibit C.
Efficacy. This License Agreement is valid without Licensor’s signature. It becomes effective upon the Licensee’s first use of the Product.
Efficacy. We will assess the difference in number of the percentage of females surviving between release and non- release treatments, as well as how survival is affected by the following variables: • Release rate (the number of male adults released/exiting a single mosquito rearing box) • Trap distance (how far the trap is from the point of release) • Site (which site replicate is being measured) We will assess the difference in female survival between release and non-release sites using general linear mixed-effects models (GLMM) with the random effect of site, a crossed random effect of trap distance, and the covariates life stage and release rate. The model will use a quasibinomial distribution and a logit link function since the response variable is recorded as a percentage. Percent efficacy and 95% confidence intervals will be calculated from the results of the GLMM. The efficacy (E) of OX5034 to kill female mosquitoes is calculated using an adaption of ▇▇▇▇▇’s formula: E=100*((C-T)/C) or E=100*(1-T/C) E = percentage efficacy in individual ovitraps from the treated area. C = percentage of untreated females surviving across all ovitraps in control areas. T = percentage of treated, i.e. fluorescent females surviving in individual ovitraps. Persistence Monitoring The ▇▇▇▇▇▇-▇▇▇▇▇ estimator will be used to characterize the persistence of the OX5034 gene in release sites. Estimated median values, 95% confidence intervals, interquartile ranges and maxima will be reported. It is anticipated that trial(s) will be initiated in 2020, pending regulatory approval, and that OX5034 trials will be completed within 24 calendar months of initiation.
Efficacy. When tested against Pseudomonas aeruginosa in 30 minutes achieves at least a 4.0 log reduction at time zero and a log reduction of 3.0 throughout the shelf life. Reference WI-8.
Efficacy. Adopting an approach that strives for continuous improvement in the quality and cost of services provided to residents by using data to find efficiencies and adjusting to changing circumstances.
Efficacy. Will have bactericidal properties similar to Acticoat AB, by demonstrating at least a 4.0 log reduction of Pseudomonas aeruginosa in 120 minutes according to procedure WB-10-03-25; • Will have bactericidal properties similar to Acticoat AB, by demonstrating at least a 3 log reduction of S. aureus in 120 minutes according to procedure WB-10-03-25; • Will maintain antimicrobial activity for a period of three days in use, by demonstrating 3 days plate to plate CZOI efficacy using procedure WB-10-03-04. 4.1.2 Absorbency The absorbency will be at least 12 g PBS/g dressing using procedure WB-10-03-11